e
`
`UNITED STATES
`PATENT AND TRADEMARK OFFICE
`
`Page 1 of 3
`P.O. Box 1450
`Alexandria, VA 22313 - 1450
`www.uspto.gov
`
`ELECTRONIC ACKNOWLEDGEMENT RECEIPT
`
`
`
`APPLICATION #
`17/721,831
`
`RECEIPT DATE /TIME
`10/19/2023 05:24:36 PM ET
`
`ATTORNEY DOCKET #
`46682-701.319
`
`Title of Invention
`
`OPHTHALMIC COMPOSITION
`
`Application Information
`
`APPLICATION TYPE
`
`Utility - Nonprovisional Application
`under 35 USC 111{a)
`
`PATENT # -
`
`CONFIRMATION # 7573
`
`PATENT CENTER # 63037722
`
`CUSTOMER # 21971
`
`CORRESPONDENCE
`ADDRESS
`
`Documents
`
`FILED BY
`
`J ennifer Vail
`
`FILING DATE
`
`04/15/2022
`
`FIRST NAMED
`INVENTOR
`
`Gregory |. OSTROW
`
`AUTHORIZED BY
`
`Erin Boyle Anderson
`
`TOTAL DOCUMENTS: 9
`
`DOCUMENT
`
`PAGES
`
`DESCRIPTION
`
`SIZE (KB)
`
`46682-701319IDS pdf
`
`46682-701319IDS-
`TRAN.LET.padf
`
`46682-701_ 319IDS-
`IDS pdf
`
`NPL_Shizhen_WANG_Molec
`ularNuclearMedicine_page_4
`17.pdf
`
`FOR_CN1323595MachineTr
`ans.pdf
`
`(1-4)
`
`(5-6)
`
`4
`
`2
`
`Transmittal Letter
`
`297 KB
`
`153 KB
`
`information Disclosure
`
`140 KB
`
`Statement (IDS) Form (SB08)
`
`Non Patent Literature
`
`131 KB
`
`10
`
`Foreign Reference
`
`777 KB
`
`

`

`Non Patent Literature
`
`757 KB
`
`Page 2 of 3
`
`Foreign Reference
`
`1888 KB
`
`Non Patent Literature
`
`2712 KB
`
`Non Patent Literature
`
`2563 KB
`
`Non Patent Literature
`
`2466 KB
`
`12
`
`38
`
`56
`
`54
`
`52
`
`NPL_US17335496OA7Aug
`2023.pdf
`
`FOR _WO2017204262A1_EF
`S.pdf
`
`NPL_US10842787Final De
`cision_ 13} uly2023.pdf
`
`NPL_US10888557Final De
`cision_ 13} uly2023.pdf
`
`NPL_US10940145Final De
`cision_ 13} uly2023.pdf
`
`Digest
`
`DOCUMENT
`
`MESSAGE DIGEST(SHA-512)
`
`46682-701319IDS pdf
`
`7BAEF 41BB6289C 70C1DFB2DAF 21F F 8B91B 36F 5F 3B 43616326
`
`493E5998FB7D1026B 16BD6ED27EFB5D00C 891C5DD58E 1506B
`
`780AF A3EBBDAB 2F 87859C 93E 23021D
`
`46682-701_319_IDS-
`TRAN.LET.pdf
`
`LIBDCE9CC38DD2491485AF 4876E 40E 4451F 471EDB25F B6653
`
`682C437BD3CBCO486C5COAL4CECOF O8EEC9IC2BF 8CDB86DF
`
`CE0822B3C213F 10FD4007AC16F 6BE 100
`
`46682-701_319IDS-IDS.pdf
`
`6113B60F C4B55C8016E 1541 156F 1E B4E16298EE1AD77F1D0D
`
`E10074E5AC078F D6DC9E 8E 1F C0A0953A415236872170F 85106
`
`8D8B48F 6470AF 0309BD2A6C076A52
`
`NPL_Shizhen_WANG_Molecula
`rNuclearMedicine_page_417.pd
`
`F395F D4888F LAQA0G6CE 3F 8CE 5EAF 22DB02276CCCC 64111328
`
`2BA8756E DA38DF C5BA518E 4D8680322713E 34B5D6803EA6FE
`
`E3EA00461238A0C9C567E 9659A57A9
`
`E267AC 2525B83CFE72E B6CF 8F 762CCC6253F 7547D5222A3C4
`
`0128D271B0C3935F 259B 3360E5175871E87002B 4A13805D7319
`
`30AB5C1D92010026DD43E025AD3D
`
`f F
`
`OR_CN1323595MachineTra
`ns.pdf
`
`

`

`NPL_US17335496OA_7Aug20
`23.pdf
`
`60A7D4602A819288EA26AC188552B9F5F0177B577CC 343ABE
`
`C2F 68968705D227EBD7E 3198DA1A8D6F 650E 100BFF 76B469D
`
`24AA604DB 76B 90406A569072A19910F
`
`Page 3 of 3
`
`FOR_W02017204262A1EFS.
`pdf
`
`7F5E9ED835999937751DE4907BBD0C2C2B72992E 39E 29E 7AF
`
`
`A5SA36AB8FEC8A5A3C 3FA0993C 9D3F 77B3A0A559AF 7F03ED
`
`
`
`
`E36A00C 34EBC5BC64BDC716F 60509BA
`
`NPL_US10842787Final Decis
`ion_ 13] uly2023.pdf
`
`AE84AD910C 30F 60B553EFFDD3B3BB7DD2DC1B6254FA3EEC
`
`57E9B82F AE 8D448F 5C 34DDE 25118929E EAE 8F 589A35CE9510
`
`6A710DF2297815C9EFFAQODD80F 9BF 8B 4
`
`NPL_US10888557_Final_Decisi
`on_ 13} uly2023.pdf
`
`
`D4186E14D697B6EE2523B459111A52FE31BD7557435374CDF 7
`
`6F 9BOFIEDE 83A39CB8450E 091A754CB5E 0EEEA4E 273A22327
`
`64F4A3515EFEFFOD3F1A8471AD8D0
`
`NPL_US10940145Final Decis
`ion_ 13} uly2023.pdf
`
`91C7AD3682466DE C3C 7D337749BA3F 010821F E 8F 6858773B8
`
`AODA0DB74896C 62523DF 06C 229E 4D84A3E 7FAEB/7DDO01D823
`
`B34F BB24F 006D119BDCAOF 9D45A53BF
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized
`by the applicant, and including page counts, where applicable. Itserves as evidence of receipt similar to a Post Card, as
`described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`if a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d)
`and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement
`Receipt will establish the filing date of the application
`
`National Stage of an International Application under 35 U.S.C. 371
`if a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C.
`371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage
`submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`if a new international application is being filed and the international application includes the necessary components for an
`international filing date (see PCT Article 11 and MPEP 1810), a Notification of the Internationa! Application Number and of the
`International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security,
`and the date shown on this Acknowledgement Receiptwill establish the international filing date of the application.
`
`